Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.44 |
| ▸ | FEN1 | P39748 | 2/20 | 0.44 |
| ▸ | STK17B | O94768 | 1/20 | 0.44 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.43 |
| ▸ | CA2 | P00918 | 6/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | LATS1 | O95835 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19490770 | 0.85 | MALT1 (0.48) | BCHEMALT1ALOX5APFEN1STK17B | |
| SCHEMBL3201557 | 0.85 | MALT1 (0.50) | BCHEMALT1CA1CA2CA12 | |
| SCHEMBL25375255 | 0.84 | BCHE (0.46) | BCHEMALT1STK17BSTK17ACA1 | |
| SCHEMBL8250962 | 0.83 | KMT2A (0.51) | BCHEMALT1STK17BSTK17ALATS1 | |
| SCHEMBL27260537 | 0.83 | P4HTM (0.50) | BCHEMALT1STK17BSTK17ACA1 | |
| SCHEMBL24205509 | 0.83 | BCHE (0.46) | BCHEMALT1ALOX5APFEN1STK17B | |
| SCHEMBL14623867 | 0.81 | MALT1 (0.46) | BCHEMALT1ALOX5APFEN1STK17B | |
| SCHEMBL22644748 | 0.80 | MALT1 (0.51) | BCHEMALT1CA1CA2CA12 | |
| SCHEMBL31190971 | 0.80 | NAMPT (0.51) | CA1CA12CA9MAPKAPK2 | |
| SCHEMBL20878669 | 0.80 | MTNR1A (0.48) | ALOX5APFEN1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022012492-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2022-01-20 | — | — | WO | disclosed |
| US-20210122754-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB SUCCINATE AND ITS NOVEL CRYSTALLINE FORMS THEREOF | NATCO PHARMA LTD (IN) | 2021-04-29 | — | — | US | disclosed |
| WO-2020140054-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. (US) | 2020-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | BCHE 4433/4885MALT1 469/4885ALOX5AP 2635/4885 |
| US-20210122754-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB SUCCINATE AND ITS NOVEL CRYSTALLINE FORMS THEREOF | RRM2B, CPS1, RRBP1 | BCHE 4867/4885MALT1 713/4885ALOX5AP 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.